Everolimus for cardiac allograft vasculopathy--every patient, at any time?

Transplantation. 2011 Jul 27;92(2):127-8. doi: 10.1097/TP.0b013e318220588f.
No abstract available

Publication types

  • Comment

MeSH terms

  • Azathioprine / therapeutic use
  • Calcineurin Inhibitors
  • Cell Proliferation / drug effects
  • Disease Progression
  • Drug Therapy, Combination
  • Everolimus
  • Heart Transplantation / immunology*
  • Heart Transplantation / pathology
  • Humans
  • Immunosuppressive Agents / pharmacology
  • Immunosuppressive Agents / therapeutic use*
  • Incidence
  • Muscle, Smooth, Vascular / pathology
  • Mycophenolic Acid / analogs & derivatives
  • Mycophenolic Acid / therapeutic use
  • Risk Factors
  • Sirolimus / analogs & derivatives*
  • Sirolimus / pharmacology
  • Sirolimus / therapeutic use
  • Vascular Diseases / epidemiology*
  • Vascular Diseases / prevention & control*

Substances

  • Calcineurin Inhibitors
  • Immunosuppressive Agents
  • Everolimus
  • Mycophenolic Acid
  • Azathioprine
  • Sirolimus